Ptc Therapeutics [PTCT] vs Axsome Therapeutics [AXSM] Detailed Stock Comparison

Ptc Therapeutics Inc.

NASDAQ
Loading...

Axsome Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Ptc Therapeutics Inc. wins in 11 metrics, Axsome Therapeutics Inc. wins in 8 metrics, with 0 ties. Ptc Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Ptc Therapeutics Inc. Axsome Therapeutics Inc. Better
P/E Ratio (TTM) 8.01 -50.54 Ptc Therapeutics Inc.
Price-to-Book Ratio -26.99 105.31 Axsome Therapeutics Inc.
Debt-to-Equity Ratio -13.19 247.03 Axsome Therapeutics Inc.
PEG Ratio 0.08 0.79 Ptc Therapeutics Inc.
EV/EBITDA 7.20 -57.70 Ptc Therapeutics Inc.
Profit Margin (TTM) 39.44% -28.69% Ptc Therapeutics Inc.
Operating Margin (TTM) -49.57% -18.38% Axsome Therapeutics Inc.
Return on Equity -332.49% -252.12% Axsome Therapeutics Inc.
Return on Assets (TTM) 23.26% -16.81% Ptc Therapeutics Inc.
Free Cash Flow (TTM) $411.18M $-93.89M Ptc Therapeutics Inc.
1-Year Return 52.21% 122.97% Axsome Therapeutics Inc.
Price-to-Sales Ratio (TTM) 3.29 14.64 Ptc Therapeutics Inc.
Enterprise Value $6.45B $9.24B Axsome Therapeutics Inc.
EV/Revenue Ratio 3.73 14.47 Ptc Therapeutics Inc.
Gross Profit Margin (TTM) 95.78% 93.71% Ptc Therapeutics Inc.
Revenue per Share (TTM) $22 $13 Ptc Therapeutics Inc.
Earnings per Share (Diluted) $8.58 $-3.69 Ptc Therapeutics Inc.
Beta (Stock Volatility) 0.55 0.47 Axsome Therapeutics Inc.
Short % of Float 12.21% 6.56% Axsome Therapeutics Inc.

Ptc Therapeutics Inc. vs Axsome Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

PTCT
AXSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Ptc Therapeutics Inc.-1.78%7.32%14.41%11.27%-6.76%-3.77%
Axsome Therapeutics Inc.5.09%-0.45%4.37%42.32%57.95%30.66%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Ptc Therapeutics Inc.52.21%67.38%88.49%865.36%322.00%322.00%
Axsome Therapeutics Inc.122.97%216.35%282.39%2,961.10%2,485.23%2,485.23%

Performance & Financial Health Analysis: Ptc Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTCTAXSM
Market Information
Market Cap i$5.69B$9.51B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i829,740592,425
90 Day Avg. Volume i1,097,593602,162
Last Close$50.82$233.47
52 Week Range$28.72 - $58.38$96.09 - $238.56
% from 52W High-12.95%-2.13%
All-Time High$78.72 (Apr 06, 2015)$238.56 (May 26, 2026)
% from All-Time High-35.44%-2.13%
Growth Metrics
Quarterly Revenue Growth-0.23%0.65%
Quarterly Earnings Growth-0.23%0.65%
Financial Health
Profit Margin (TTM) i0.39%-0.29%
Operating Margin (TTM) i-0.50%-0.18%
Return on Equity (TTM) i-3.32%-2.52%
Debt to Equity (MRQ) i-13.19247.03
Cash & Liquidity
Book Value per Share (MRQ)$-2.52$1.74
Cash per Share (MRQ)$23.50$6.31
Operating Cash Flow (TTM) i$711.20M$-93,405,000
Levered Free Cash Flow (TTM) i$211.76M$-29,420,876
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Ptc Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTCT (Apr 13, 2026)AXSM (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i8.01-50.54
Forward P/E i28.2729.85
PEG Ratio i0.080.79
Price to Sales (TTM) i3.2914.64
Price to Book (MRQ) i-26.99105.31
Market Capitalization
Market Capitalization i$5.69B$9.51B
Enterprise Value i$6.45B$9.24B
Enterprise Value Metrics
Enterprise to Revenue i3.7314.47
Enterprise to EBITDA i7.20-57.70
Risk & Other Metrics
Beta i0.550.47
Book Value per Share (MRQ) i$-2.52$1.74

Financial Statements Comparison: Ptc Therapeutics Inc. vs Axsome Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPTCT (2025)AXSM (2025)
Revenue/Sales i1.73B638.50M
Cost of Goods Sold i47.01M47.48M
COGS % of Revenue i2.7%7.4%
Gross Profit i1.68B591.02M
Gross Margin i97.3%92.6%
Research & Development i455.25M183.28M
Operating Income (EBIT) i856.51M-169.24M
Operating Margin i49.5%-26.5%
EBITDA i877.24M-160.17M
EBITDA Margin i50.7%-25.1%
Pre-Tax Income i696.62M-183.70M
Pre-Tax Income % of Revenue i40.3%-28.8%
Income Tax i13.98M-530,000
Income Tax % of Revenue i0.8%-0.1%
Net Income (Profit) i682.64M-183.17M
Profit Margin i39.4%-28.7%

Balance Sheet & Liquidity Metrics

MetricPTCT (2025)AXSM (2025)
Cash & Equivalents i984.65M322.93M
Total Current Assets i2.27B588.99M
Total Current Assets % of Revenue i131.4%92.2%
Total Current Liabilities i968.43M378.84M
Total Current Liabilities % of Revenue i56.0%59.3%
Long-Term Debt i2.12B145.13M
Long-Term Debt % of Revenue i122.6%22.7%
Total Shareholders Equity i-205.31M88.30M
Retained Earnings i-2.96B-1.31B
Retained Earnings % of Revenue i-171.3%-204.5%
Property, Plant & Equipment i80.05M562,000

Cash Flow Statement Comparison

MetricPTCT (2025)AXSM (2025)
Operating Cash Flow i689.58M-185.86M
Operating Cash Flow % of Revenue i39.8%-29.1%
Capital Expenditures i-8.79M-480,000
Free Cash Flow i411.18M-93.89M
FCF Margin i23.8%-14.7%
Debt Repayment i-1.61M-334.11M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPTCTAXSM
Shares Short i8.85M2.83M
Short Ratio i7.234.92
Short % of Float i12.21%6.56%
Shares Outstanding i81.47M50.88M
Float Shares i72.99M43.24M
% Held by Insiders i7.43%15.47%
% Held by Institutions i113.38%76.52%
% Held by Public i-20.81%8.01%

Dividend Analysis & Yield Comparison: Ptc Therapeutics Inc. vs Axsome Therapeutics Inc.

MetricPTCTAXSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A